Attovia Therapeutics, Inc. (ATTO)
13.83
-0.67
(-4.62%)
USD |
NASDAQ |
Oct 23, 16:00
13.83
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 631.36M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 1403.02 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0384 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that creates next-generation biologic medicines for immune-mediated diseases. It was founded in 2022 and is headquartered in San Carlos, CA. |
| URL | http://www.attovia.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Nov. 11, 2026 (est.) |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that creates next-generation biologic medicines for immune-mediated diseases. It was founded in 2022 and is headquartered in San Carlos, CA. |
| URL | http://www.attovia.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Nov. 11, 2026 (est.) |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |